Currently Viewing:
Genitourinary Cancers Symposium
Dr Donna Hansel Discusses Challenges When Treating Advanced Bladder Cancer
May 04, 2018
Dr Joe O'Sullivan: We Are Getting Better at Treating Prostate Cancer Earlier
April 29, 2018
Dr Joe O'Sullivan: Numerous Prostate Cancer Therapies Is a Challenge for Clinical Trials
April 19, 2018
Dr Joe O'Sullivan Explains Education of Patients and Physicians on Molecular Therapies
April 03, 2018
Dr Donna Hansel on Targeting mTOR in Advanced Bladder Cancer
March 28, 2018
Dr Christopher Kane Explains How MRI Is Influencing Prostate Cancer Diagnosis
February 28, 2018
Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer
February 14, 2018
Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer
February 11, 2018
Docetaxel Plus Hormone Therapy Improved QoL, Cost Effectiveness in Prostate Cancer
February 10, 2018
Medicaid Expansion Led to Earlier Stage at Diagnosis of Testicular Cancer
February 10, 2018
Currently Reading
Daily IGRT in Prostate Cancer Reduces Risk of Recurrence, Increases Risk of Second Cancer
February 10, 2018
Use of Biomarkers to Identify Patients, Therapies for Neoadjuvant Chemotherapy
February 10, 2018
Combining Radiation and Immunotherapy in Patients With Bladder Cancer
February 09, 2018
Guidelines for Management of Muscle-Invasive Bladder Cancer
February 09, 2018
Is There Evidence for Local Treatment for Newly Diagnosed Metastatic Prostate Cancer?
February 09, 2018
Dr Joe O'Sullivan on Molecular Therapies in Prostate Cancer
February 09, 2018
Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC
February 09, 2018
Apalutamide Significantly Improved Metastasis-Free Survival in Men With nmCRPC
February 09, 2018

Daily IGRT in Prostate Cancer Reduces Risk of Recurrence, Increases Risk of Second Cancer

Jaime Rosenberg
Daily image-guided radiotherapy, when compared to weekly control, decreases the risk of recurrence and rectal toxicity, but is associated with an increased risk of second cancer, according to study results presented at the 2018 Genitourinary Cancers Symposium.
During a session at the 2018 Genitourinary Cancers Symposium, study results showed that daily image-guided radiotherapy (IGRT), when compared to weekly control, decreases the risk of recurrence and rectal toxicity, but is associated with an increased risk of second cancer.

“While there is a strong rational for prostate cancer IGRT, optimal frequency of the control is not clearly identified,” said Renaud de Crevoisier, MD, PhD, professor, University of Rennes, radiation-oncologist, Regional Cancer Center. “It may be possible to correct only for the systematic error by doing a control on day 1, 2, 3, and weekly, or it may be necessary to correct for systematic and random error by doing a daily control.”

The phase 3 randomized trial comprised of 2 steps: the first was a feasibility step for the first 5 patients. Then, 470 patients from 21 centers were randomized 1:1 between 2 arms: weekly control or daily control between June 2007 and November 2012.

According to Crevoisier, the hypothesis was to detect a minimum of a 12% difference in 5-year disease-free survival (DFS) between the groups. The patients were stratified between center, prognostic group, total dose, and androgen deprivation therapy. The median follow-up was 4.1 years. Secondary outcomes included overall survival (OS) and toxicity. Post-hoc analyses included biochemical progression-free interval, clinical progression-free interval and second cancer-free interval.

For toxicity, acute rectal bleeding greater than grade 1 decreased significantly in the daily control group (6% versus 11%). Rectal toxicity, BPFI, and clinical recurrence also decreased significantly in the daily control group.

Surprisingly, OS decreased in the daily control group, said Crevoisier. The risk of death increasedby a factor of 2. Looking at second cancer incidence in the post-hoc analysis, the risk of second incidence was also multiplied by 2 in the daily control group.

“Compared to weekly control, by improving targeting, daily control in prostate cancer IGRT significantly decreases the risks of recurrence and rectal toxicity but is associated with an increased risk of second cancer,” concluded Crevoisier. “Longer follow-up is however clearly needed to assess the rate of radiation-associated malignancies.”

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!